Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Abstract

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

K M Merchant, G S Gill, D W Harris, R M Huff, M J Eaton, K Lookingland, B S Lutzke, R B Mccall, M F Piercey, P J Schreur, V H Sethy, M W Smith, K A Svensson, A H Tang, P F Vonvoigtlander and R E Tenbrink
Journal of Pharmacology and Experimental Therapeutics December 1996, 279 (3) 1392-1403;
K M Merchant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G S Gill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D W Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R M Huff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M J Eaton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Lookingland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B S Lutzke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R B Mccall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M F Piercey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P J Schreur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V H Sethy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M W Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K A Svensson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A H Tang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P F Vonvoigtlander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R E Tenbrink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Dopamine D2-like receptors play an important role in the pharmacotherapy of psychotic disorders. Molecular and cellular techniques have identified distinct gene products (D2-long, D2-short, D3 and D4) displaying the D2 receptor pharmacology. However, the contribution of each subtype in antipsychotic effects of or their physiological role remain unclear. Here we describe the pharmacological effects of a selective D4 antagonist, U-101387. U-101387 displayed moderately high affinity (Ki = 10 nM) and selectivity for the dopamine D4.2 receptor expressed in clonal cell lines. It lacked measurable affinity for not only other dopamine receptors but also noradrenalin, serotonin and histamine receptor families (Ki > 2000 nM). It fully and dose-dependently antagonized quinpirole-induced cAMP inhibition (without producing any effect by itself) in stably transfected cells. U-101387 also displayed excellent oral bioavailability, brain penetration and other pharmacokinetic characteristics. Unlike classical neuroleptics (e.g., haloperidol), U-101387 neither blocked acute behavioral effects of amphetamine or apomorphine nor did it alter spontaneous locomotion by itself. Additionally, U-101387 was without effect in behavioral and biochemical tests predictive of extrapyramidal and neuroendocrine side effects. Consistent with the lack of autoreceptor function of D4, acute administration of U-101387 failed to alter dopamine neuronal firing by itself or reverse the inhibition produced by dopamine agonists and to affect monoamine turnover in areas innervated by the mesencephalic or hypothalamic dopamine neurons. However, U-101387 potently induced c-fos mRNA expression in the infralimbic/ventral prelimbic cortex to a level similar to that produced by the atypical antipsychotic, clozapine. This is consistent with the predominantly cortical distribution of the D4 receptor. Taken together, these results demonstrate that the D4-selective antagonist, U-101387, produces effects that are distinct from those of the nonselective D2 antagonists as well as D3-preferring agents. U-101387 offers a unique tool to understand the role of dopamine D4 receptors in diseases involving central dopamine systems.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 279, Issue 3
1 Dec 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

K M Merchant, G S Gill, D W Harris, R M Huff, M J Eaton, K Lookingland, B S Lutzke, R B Mccall, M F Piercey, P J Schreur, V H Sethy, M W Smith, K A Svensson, A H Tang, P F Vonvoigtlander and R E Tenbrink
Journal of Pharmacology and Experimental Therapeutics December 1, 1996, 279 (3) 1392-1403;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

K M Merchant, G S Gill, D W Harris, R M Huff, M J Eaton, K Lookingland, B S Lutzke, R B Mccall, M F Piercey, P J Schreur, V H Sethy, M W Smith, K A Svensson, A H Tang, P F Vonvoigtlander and R E Tenbrink
Journal of Pharmacology and Experimental Therapeutics December 1, 1996, 279 (3) 1392-1403;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics